| Name | ASM-024 |
| Description | ASM-024, a potent nicotinic receptor agonist, is a small molecule synthetic piperazine compound that promotes different targets and signaling pathways of β2-adrenergic receptors mediating smooth muscle relaxation, and is a potential compound for the treatment of asthma and chronic obstructive bronchitis with anti-inflammatory activity. |
| In vitro | Incubation of HBSMC cells with ASM-024 did not induce significant production of cAMP compared to salbutamol or formoterol treated cells.[1] Fifteen minutes of incubation of hBSMC with ASM-024 alone had no effect on [Ca2+]i. However, a 10 minute pre-treatment with ASM-024 decreased [Ca2+]i rise in cells challenged with 10-6 M histamine or methacholine.[1] |
| In vivo | ASM-024 increased in vitro relaxation response to maximally effective concentration of short—acting beta-2 agonists in dog and human bronchi.[1] ASM-024 induces smooth muscle relaxation of β2-AR desensitized tracheas.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 2.34 mg/mL (10.03 mM), Sonication is recommended.
|
| Keywords | Nicotinic Receptor | ASM-024 cation | ASM-024 | ASM024 | ASM 024 |
| Inhibitors Related | Adiphenine hydrochloride | Levamisole hydrochloride | Ethyl (triphenylphosphoranylidene) acetate | Urethane | Hexamethonium Bromide | Ribavirin | Adenine | Mitotane | Choline chloride | Propoxur | N,N-Dicyclohexylcarbodiimide | Arecoline |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
United States
